AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic Exercises Option to License Daiichi\u2019s IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn\u2019s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alpine Immune Sciences"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Morphic Therapeutic"},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synlogic Announces Termination of AbbVie Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Synlogic"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Morphic Therapeutic"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Amgen Inc"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Doses First Patient in Clinical Study of Microbiome Metabolic Therapy KB295 to treat Mild to Moderate Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kaleido Biosciences"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Alivio Therapeutics"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the IDSA IDWeek Conference 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$22.5 Million","upfrontCash":"$14.0 million","newsHeadline":"Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Anagram Therapeutics"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$990.0 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Protagonist Therapeutics"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn\u2019s Disease, and Ulcerative Colitis with Allocetra Immunotherapy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company\u2019s Oral Drug Delivery System in Targeting the Colon","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 Inflammasome Inhibitor","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Artizan Bioscience"},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Reprocell"},{"orgOrder":0,"company":"Surrozen","sponsor":"Consonance-HFW","pharmaFlowCategory":"D","amount":"$212.0 million","upfrontCash":"$92.0 million","newsHeadline":"Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination Focused on Wnt Biology and Tissue Regeneration","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation IBD Ventures Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Progenity Receives Funding from Crohn\u2019s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043 at 2021 Digestive Disease Week Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Provides Results from Key Study for Its Targeted Therapeutics Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Presents Preclinical Data Showing Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eligo Bioscience"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alivio Therapeutics"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma GmbH","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360\u2122 Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease at ECCO 2021 Virtual Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Metacrine"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Finch Therapeutics"},{"orgOrder":0,"company":"Vitality","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Vitality"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kaleido Biosciences"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Announces Several Patents Granted by USPTO, Strengthening the Company\u2019s Intellectual Property Position in Ingestible Therapeutics Technologies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Reprocell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Extends Partnership Agreement with REPROCELL","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents Preclinical Data at Crohn\u2019s & Colitis Foundation\u2019s\u00ae IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Second Genome"},{"orgOrder":0,"company":"EsoCap","sponsor":"Upadia Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EsoCap and Upadia Sign Exclusive Licensing Agreement Combining Eso Cap Technology with Upadia Antibodies for The Treatment of Barrett\u2019s Esophagus","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"EsoCap"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn\u2019s and Colitis Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kaleido Biosciences"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO\u201922","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Progenity"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Artizan Bioscience"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem and the Crohn\u2019s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of A New Therapeutic Approach in Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Inotrem"},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Second Genome"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Comera Life Sciences"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Athos Therapeutics"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Receives Orphan Drug Designation from the FDA for Mycapssa (Oral Octreotide) for the Treatment of Carcinoid Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amryt Pharma"},{"orgOrder":0,"company":"Enterome","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.7 million","newsHeadline":"Enterome Signs Major Strategic R&D Collaboration with Nestl\u00e9 Health Science to Develop and Commercialize New AllerMimics\u2122 and EndoMimics\u2122 Immunotherapies for Food Allergies and Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Enterome"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Finch Therapeutics"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate\u2019s PNV-6005 as a Potential Treatment for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Adial Pharmaceuticals"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Intract Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SGS\u2019s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Intract Pharma"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Receives Funding From the Crohn\u2019s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Inotrem"},{"orgOrder":0,"company":"ClostraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClostraBio Announces Breakthrough Publication Describing Targeted Delivery of Metabolite to Gastrointestinal Tract via Oral Nanoparticles; Appoints CEO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ClostraBio"},{"orgOrder":0,"company":"BITT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BITT Provides Update on DOMab Platform and CD40 Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BITT"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Jaguar Health"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Celsius Therapeutics"},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Group","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Trobix Bio"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ThirtyFiveBio"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$5.0 million","newsHeadline":"Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Innate Pharma"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Tryp Therapeutics"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Brigham and Women\u2019s Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Finch Therapeutics"},{"orgOrder":0,"company":"Pan-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pan-Biome Pharmaceuticals, A Startup Focused on Age-Related Diseases and Increasing Human Healthspan, Reports Positive Results in A Preclinical Trial of Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Pan-Biome Pharmaceuticals"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Mozart Therapeutics"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces $8 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Spyre Therapeutics"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Fairmount Funds Management","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Aeglea BioTherapeutics"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Receives Milestone Funding from the Crohn\u2019s & Colitis Foundation IBD Ventures Program to Advance its Inflammatory Bowel Disease Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Inotrem"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Palisade Bio"},{"orgOrder":0,"company":"DP Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"DP Technology"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Peptide","graph2":"EnteraBio Ltd"},{"orgOrder":0,"company":"Parvus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Parvus Therapeutics"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Equillium"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Matinas BioPharma"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s and Colitis Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ with the Support of Impulsion PME","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Neurenati Therapeutics"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"}]

Find Novel Gastroenterology Drugs in Preclinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration with Strand Life Sciences grants Palisade Bio access to an advanced lead program, PALI-2108, which is currently in the early stages of trials for treating Ulcerative Colitis.

            Lead Product(s): PALI-2108

            Therapeutic Area: Gastroenterology Product Name: PALI-2108

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Strand Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 23, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will be used to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease.

            Lead Product(s): NEU-001

            Therapeutic Area: Gastroenterology Product Name: NEU-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Investissement Québec

            Deal Size: $2.9 million Upfront Cash: Undisclosed

            Deal Type: Financing April 18, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Entera Bio & Opko Health is developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: OPKO Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies, including PVT-401, for Inflammatory Bowel Disease.

            Lead Product(s): PVT-401

            Therapeutic Area: Gastroenterology Product Name: PVT-401

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor. It is being evaluated in preclinical studies for the treatment of Inflammatory Bowel Disease & Atopic Dermatitis.

            Lead Product(s): DPT0218

            Therapeutic Area: Gastroenterology Product Name: DPT0218

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug. It is being evaluated in preclinical studies for the treatment of moderate-to-severe ulcerative colitis.

            Lead Product(s): PALI-2108

            Therapeutic Area: Gastroenterology Product Name: PALI-2108

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will be used for the development of Palisade's lead program, PALI-2108, a microbiota-activated PDE4 inhibitor prodrug, for the treatment of moderate-to-severe ulcerative colitis.

            Lead Product(s): PALI-2108

            Therapeutic Area: Gastroenterology Product Name: PALI-2108

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Crohn’s and Colitis Foundation

            Deal Size: $0.5 million Upfront Cash: Undisclosed

            Deal Type: Funding December 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            An orally administered LNC-delivered small oligonucleotide that specifically targets TNFα mRNA synthesis & inhibit IL-17A mRNA synthesis. It is being evaluated in preclinical studies for acute colitis & acute psoriasis.

            Lead Product(s): Oligonucleotide-based Therapy

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EQ302 is an orally delivered stapled peptide inhibitor of IL-15 and IL-21 derived from EQ102. It is being evaluated in pre-clinical studies for the treatment of gastrointestinal diseases.

            Lead Product(s): EQ302

            Therapeutic Area: Gastroenterology Product Name: EQ302

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity